Equities

C4 Therapeutics Inc

CCCC:NSQ

C4 Therapeutics Inc

Actions
  • Price (USD)5.51
  • Today's Change-0.37 / -6.29%
  • Shares traded763.71k
  • 1 Year change+220.35%
  • Beta3.0408
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform3
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for C4 Therapeutics Inc have a median target of 14.00, with a high estimate of 39.00 and a low estimate of 8.00. The median estimate represents a 154.08% increase from the last price of 5.51.
High607.8%39.00
Med154.1%14.00
Low45.2%8.00

Earnings history & estimates in USD

On Oct 31, 2024, C4 Therapeutics Inc reported 3rd quarter 2024 losses of -0.35 per share. This result exceeded the -0.38 consensus loss of the 7 analysts covering the company and exceeded last year's 3rd quarter results by 36.36%.
The next earnings announcement is expected on Feb 20, 2025.
Average growth rate+4.03%
C4 Therapeutics Inc reported annual 2023 losses of -2.65 per share on Feb 22, 2024.
Average growth rate+7.89%
More ▼

Revenue history & estimates in USD

C4 Therapeutics Inc had 3rd quarter 2024 revenues of 15.36m. This bettered the 4.60m consensus of the 5 analysts covering the company. This was 308.67% above the prior year's 3rd quarter results.
Average growth rate+61.42%
C4 Therapeutics Inc had revenues for the full year 2023 of 20.76m. This was 33.25% below the prior year's results.
Average growth rate-9.14%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.